What would be our fair market cap considering this Gemini 3 output?
As of today the majority of solid tumors remain refractory, meaning once our trial hopefully confirms the whole solid tumor market actually will be bigger than recent numbers indicate.
"When analyzing the proportion of checkpoint inhibitor (ICI)-refractory cancers compared to all solid tumors, it is important to distinguish between the entire cancer population and those actually receiving treatment.
While ICIs (like Pembrolizumab or Nivolumab) have revolutionized oncology, the majority of solid tumors remain either primarily or secondarily refractory.
1. The Epidemiological Perspective (The "Big Picture"
Research by experts such as Haslam & Prasad has tracked how many patients with solid tumors are theoretically eligible for ICI therapy versus those who actually benefit.
| Category | Proportion of All Cancer Patients (Estimated) |
|---|---|
| Eligible for ICI therapy | approx. 43 – 50% |
| Responders (Benefit from therapy) | approx. 12 – 15% |
| Refractory / Non-responders | approx. 85 – 88% |
In short, out of the total population of patients with solid tumors, only about 12.5% experience a long-term benefit from ICI monotherapy. The remaining ~87% are either ineligible for the treatment (e.g., "cold" tumors like most pancreatic cancers) or do not respond to it.
2. Resistance Rates in Treated Patients (The Clinical View)
Among the subset of patients who actually receive ICIs, refractoriness is categorized into two forms:
* Primary Refractoriness (Intrinsic Resistance): The tumor never responds to the treatment from the start.
* This affects 60% to 70% of treated patients across various indications.
* Example: In non-small cell lung cancer (NSCLC), a large majority of patients show either no response or early progression.
* Secondary/Acquired Refractoriness: The tumor initially responds but eventually develops resistance and progresses.
* This affects a significant portion of initial responders, typically occurring after 6 to 24 months of treatment.
3. Why are so many tumors refractory?
The high rate of refractoriness is largely due to the fact that many solid tumors are "immunologically cold." Key drivers include:
* Low Tumor Mutational Burden (TMB): The immune system does not recognize the tumor as "foreign" because it lacks enough mutations to create neoantigens.
* Immunosuppressive Microenvironment: The tumor protects itself using regulatory cells (Tregs, MDSCs) or signaling molecules (like TGF-beta) that shut down T-cell activity.
* MHC Class I Loss: The tumor "hides" its antigens, meaning T-cells cannot find a target even if the "brakes" (checkpoints) are removed.
Summary
Across all solid tumors, refractoriness is the rule, not the exception. While specific cancers like melanoma show high response rates (40–60%), the response rate across unselected solid tumors (such as many gastrointestinal, prostate, or breast cancers) is often below 10%, leading to a global refractoriness rate of over 85%.
Would you like me to go into more detail regarding the mechanisms of primary resistance in a specific tumor type, such as lung or colorectal cancer?"
As of today the majority of solid tumors remain refractory, meaning once our trial hopefully confirms the whole solid tumor market actually will be bigger than recent numbers indicate.
"When analyzing the proportion of checkpoint inhibitor (ICI)-refractory cancers compared to all solid tumors, it is important to distinguish between the entire cancer population and those actually receiving treatment.
While ICIs (like Pembrolizumab or Nivolumab) have revolutionized oncology, the majority of solid tumors remain either primarily or secondarily refractory.
1. The Epidemiological Perspective (The "Big Picture"
Research by experts such as Haslam & Prasad has tracked how many patients with solid tumors are theoretically eligible for ICI therapy versus those who actually benefit.
| Category | Proportion of All Cancer Patients (Estimated) |
|---|---|
| Eligible for ICI therapy | approx. 43 – 50% |
| Responders (Benefit from therapy) | approx. 12 – 15% |
| Refractory / Non-responders | approx. 85 – 88% |
In short, out of the total population of patients with solid tumors, only about 12.5% experience a long-term benefit from ICI monotherapy. The remaining ~87% are either ineligible for the treatment (e.g., "cold" tumors like most pancreatic cancers) or do not respond to it.
2. Resistance Rates in Treated Patients (The Clinical View)
Among the subset of patients who actually receive ICIs, refractoriness is categorized into two forms:
* Primary Refractoriness (Intrinsic Resistance): The tumor never responds to the treatment from the start.
* This affects 60% to 70% of treated patients across various indications.
* Example: In non-small cell lung cancer (NSCLC), a large majority of patients show either no response or early progression.
* Secondary/Acquired Refractoriness: The tumor initially responds but eventually develops resistance and progresses.
* This affects a significant portion of initial responders, typically occurring after 6 to 24 months of treatment.
3. Why are so many tumors refractory?
The high rate of refractoriness is largely due to the fact that many solid tumors are "immunologically cold." Key drivers include:
* Low Tumor Mutational Burden (TMB): The immune system does not recognize the tumor as "foreign" because it lacks enough mutations to create neoantigens.
* Immunosuppressive Microenvironment: The tumor protects itself using regulatory cells (Tregs, MDSCs) or signaling molecules (like TGF-beta) that shut down T-cell activity.
* MHC Class I Loss: The tumor "hides" its antigens, meaning T-cells cannot find a target even if the "brakes" (checkpoints) are removed.
Summary
Across all solid tumors, refractoriness is the rule, not the exception. While specific cancers like melanoma show high response rates (40–60%), the response rate across unselected solid tumors (such as many gastrointestinal, prostate, or breast cancers) is often below 10%, leading to a global refractoriness rate of over 85%.
Would you like me to go into more detail regarding the mechanisms of primary resistance in a specific tumor type, such as lung or colorectal cancer?"
5
